Lytgobi

futibatinib

Approval

ApplicationNDA 214801
Approval dateSep 30, 2022
Approval year2022
SponsorTaiho Oncology

FDA-approved use

To treat intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements

Approval package

Query with Claude

The fda-analyst skill answers natural-language questions about this approval by fetching the relevant FDA review PDFs at query time.

git clone https://github.com/cbetz/trove
cp -r trove/skills/fda-analyst ~/.claude/skills/

Example prompts for Lytgobi: